|
|
|
|
||
Re: NERV's drug MIN-101 for schizophrenia/negative symptoms fails phase 3 studyOne year ago ACAD was trading in the $24-25 range. One year from now, if it is still an independent concern, it will be trading at least 60% higher than what it is right now. On most non-news days, ACAD trades in tandem with the IBB. Today, unfortunately, much of the sector is down. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
16640 | Re: NERV's drug MIN-101 for schizophrenia/negative symptoms fails phase 3 study | jim_pd | 2 | 5/29/2020 12:44:39 PM |